Innovative Cellular Therapeutics - About the company
Innovative Cellular Therapeutics is a series C company based in Shanghai (China), founded in 2009. It operates as a Developer of CAR-T cell therapies for blood cancers and solid tumors. Innovative Cellular Therapeutics has raised $97.1M in funding from investors like CDH, ShenZhen GTJA Investment Group and Volcanics Venture. The company has 3896 active competitors, including 1322 funded and 904 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Alnylam.
Company Details
Developer of CAR-T cell therapies for blood cancers and solid tumors. The company has a CoupledCAR technology platform to develop a pipeline of drugs for colorectal, thyroid, pancreatic, and lung cancer.
- Website
- www.ictbio.com/
- Email ID
- *****@ictbioinc.com
- Phone Number
- +86 **********
Key Metrics
Founded Year
2009
Location
Shanghai, China
Stage
Series C
Total Funding
$97.1M in 3 rounds
Latest Funding Round
Ranked
199th among 3896 active competitors
Employee Count
15 as on Aug 31, 2026
Similar Companies
Sign up to download Innovative Cellular Therapeutics' company profile
Innovative Cellular Therapeutics's funding and investors
Innovative Cellular Therapeutics has raised a total funding of $97.1M over 3 rounds. Its first funding round was on Apr 24, 2018. Its latest funding round was a Series C round on Sep 06, 2021 for $*****. 1 investor participated in its latest round. Innovative Cellular Therapeutics has 7 institutional investors.
Here is the list of recent funding rounds of Innovative Cellular Therapeutics:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Sep 06, 2021 | 7313415 | Series C | 8989800 | 9118998 | 8834451 | 5859873 |
Dec 17, 2019 | 5752383 | Series B | 9039129 | 6736121 | 5762428 | 8318299 |
Apr 24, 2018 | 6113926 | Series B | 6350820 | 4310458 |
Access funding benchmarks and valuations. Sign up today!View details of Innovative Cellular Therapeutics's funding rounds and investors
Innovative Cellular Therapeutics' founders and board of directors
Founder? Claim ProfileInnovative Cellular Therapeutics' employee count trend
Innovative Cellular Therapeutics has 15 employees as of Aug 26. Here is Innovative Cellular Therapeutics's employee count trend over the years:
Uncover Innovative Cellular Therapeutics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Innovative Cellular Therapeutics's Competitors and alternates
Top competitors of Innovative Cellular Therapeutics include Jazz Pharmaceuticals, BeiGene and Alnylam. Here is the list of Top 10 competitors of Innovative Cellular Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
3rd | Alnylam 2002, Cambridge (United States), Public | Developer of RNA interference-based therapeutics for multiple disorders | $17M | 80/100 | |
4th |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
5th | Spark Therapeutics 2013, Philadelphia (United States), Acquired | Developer of gene therapy for rare diseases | $82.8M | 73/100 | |
6th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
7th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
8th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
9th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
10th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
199th |  Innovative Cellular Therapeutics 2009, Shanghai (China), Series C | Developer of CAR-T cell therapies for blood cancers and solid tumors | $97.1M | 60/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Innovative Cellular Therapeutics's competitors? Click here to see the top ones
Innovative Cellular Therapeutics's Investments and acquisitions
Innovative Cellular Therapeutics has made no investments or acquisitions yet.
Reports related to Innovative Cellular Therapeutics
Here is the latest report on Innovative Cellular Therapeutics's sector:
News related to Innovative Cellular Therapeutics
Filter this listMedia has covered Innovative Cellular Therapeutics for a total of 3 events in the last 1 year.
•
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal CancerTMC•Nov 10, 2025•Lyell Immunopharma, Innovative Cellular Therapeutics
•
Thor Equities Signs First Tenant at Office-to-Lab Conversion in RockvilleCommercial Observer•Aug 18, 2023•Innovative Cellular Therapeutics, Thor Equities
•
Fortress Biotech Appoints Lucy Lu, M.D., to its Board of DirectorsGlobeNewswire•Dec 19, 2022•Fortress Biotech, Innovative Cellular Therapeutics
•
ICT injected with $40m in series CGlobal Corporate Venturing•Sep 07, 2021•Innovative Cellular Therapeutics, CDH, Salaso
•
Innovative Cellular Therapeutics Receives FDA Clearance of IND Application to Initiate a Phase 1 Clinical Trial for GCC19CART, a CoupledCAR® Platform Product Candidate for Relapsed or Refractory Metastatic Colorectal CancerPipelinereview•Sep 02, 2021•Innovative Cellular Therapeutics
•
Innovative Cellular Therapeutics Announces Acceptance of Abstract on its Novel CoupledCAR® Technology for Treating Colorectal Cancer for Oral Presentation at the 23rd American Society of Gene & Cell Therapy (ASGCT) Annual MeetingGlobeNewswire•Apr 14, 2020•Innovative Cellular Therapeutics
•
Innovative Cellular Therapeutics Secures Equity Financing to Advance its Next Generation Liquid and Solid Tumor CAR-T ProgramsGlobeNewswire•Dec 17, 2019•Innovative Cellular Therapeutics
•
Innovative Cellular Therapeutics Innovative Cellular Therapeutics Announces FDA Clearance of IND for its Dominant Negative PD-1 “Armored” Next Generation CAR-T Cell TherapyPipelinereview•Dec 04, 2019•Innovative Cellular Therapeutics
•
Innovative Cellular Therapeutics Announces Successful Completion of Pre-IND Meeting With FDAGlobeNewswire•Apr 10, 2019•Innovative Cellular Therapeutics
•
Innovative Cellular Therapeutics Announces Opening of U.S. Office and Appointment of New Members to Executive Leadership TeamPM360 Magazine•Mar 06, 2019•Innovative Cellular Therapeutics
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Innovative Cellular Therapeutics
Explore our recently published companies
- Stone - London based, 2017 founded, Unfunded company
- TechGraphx & Printing - Newark based, 1999 founded, Unfunded company
- Andrus Hospitality - United States based, 2016 founded, Unfunded company
- the travelers travel - Hayward based, Unfunded company
- Iotelinfotech - Unfunded company
- EB5 Marketplace - New York City based, 2012 founded, Unfunded company
